Barclays Maintains Overweight on Omada Health, Lowers Price Target to $24
Benzinga Newsdesk 3 days ago
Analyst RatingsNewsPrice Target
Barclays analyst Saket Kalia maintains Omada Health (NASDAQ:OMDA) with a Overweight and lowers the price target from $27 to $24.
Barclays analyst Saket Kalia maintains Omada Health (NASDAQ:OMDA) with a Overweight and lowers the price target from $27 to $24.